Dr. Marwan Bukhari (editor of Rheumatology) has written an editorial wherein he suggests that true remission is hard to achieve. He notes that "remission as a target is a noble objective that we should all aspire to but we should not chastise our practice if we do not achieve it, as more and more evidence suggests that we should consider it the ideal but not the norm."
All News
Dr. Jack Cush discusses the news from the past week on RheumNow.com - including the SEAM trial, MRI guided T2T, biologics and infection, contraceptive use, ANA negative lupus, etc.
Withholding intravenous abatacept (Orencia) for longer than a month before hip or knee arthroplasty among patients with rheumatoid arthritis (RA) did not lower the risk for postoperative infection, a retrospective claims-based analysis found.
The SEAM-PsA study examined the efficacy of methotrexate monotherapy, etanercept monotherapy or the combination of MTX and ETN in psoriatic arthritis patients, and found that ETN monotherapy was equivalent to combination therapy - and that both were superior to MTX alone in clinical (ACR and MDA) and radiographic responses.
A group of French researchers have pooled their interests to identify the challenges ahead in the management of patients with systemic lupus erythematosus (SLE).
Dr. Jack Cush reviews this past week's news and reports from RheumNow.com:
Specialty tier drugs, including biologics, accounts for nearly half of all medication spending by Medicare Part D patients. High out-of-pocket costs for these patients is a major concern.
Dr. Jack Cush reviews new journal articles, news reports, and more from the past week on RheumNow.com.
Research from the NEJM shows that oral antibiotic therapy was noninferior to intravenous antibiotic therapy when used during the first six weeks for complex orthopedic infections.
Dr Jack Cush reviews the news from the past week at RheumNow.com.
A subanalysis of the early rheumatoid arthritis (RA) "IMPROVED" study has shown that changes in RA-autoantibody levels are not associated with disease activity or or long-term drug response, but instead reflect intensity of immunosuppression.
Despite striking improvements in survival among patients with systemic lupus erythematosus (SLE) in recent decades -- from 1-year survival of less than 50% before the introduction of prednisone to 90% today in most specialized treatment centers -- many challenges remain in this perplexing, multis
Alcohol, smoking and obesity have all been shown to influence the risk and activity of rheumatoid arthritis (RA) and may also influence response to therapy. This study assesssed whether smoking would influence response to rituximab (RTX) in RA.
A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.
Tocilizumab (Actemra) was effective for refractory giant cell arteritis (GCA) in real-world practice, although serious infections occurred relatively frequently, Spanish investigators reported.
Dr. Jack Cush discusses the highlights from the past week on RheumNow.com:
A current meta-analysis of safety and efficacy of combination bDMARD treatment in RA patients shows that combination treatments increase serious advese event (SAE) risks, and the risk for serious infections in particular.
Reuters reports that Bristol-Myers Squibb (BMS) has announced its intention to buy Celgene Corp for nearly $74 billion in a cash-and-stock deal.
Dr. Jack Cush reviews the news and journals for the beginning of 2019. All from RheumNow.com.
Best wishes for a charmed 2019! My advice: 1. Just show up. 2. If you can, then you must do. 3. Live each day as if it twas your 1st day/last day/make or break day. 4. Teach.
This annual appraisal of hallmark moments, news and research articles from 2018 are gleaned from that published in RheumNow during the last year and filtered by other news sources and literature review. The top 10 list herein is rooted in what rheumatologists should know and what will likel
